There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on T2 Biosystems (NASDAQ:TTOO), Pacira Pharmaceuticals (NASDAQ:PCRX) and CymaBay Therapeutics (NASDAQ:CBAY) with bullish sentiments.
T2 Biosystems (TTOO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on T2 Biosystems, with a price target of $14. The company’s shares closed yesterday at $5.28.
Selvaraju commented:
“Our price target is derived from an estimated market value of the firm of $675M, which includes a discounted cash flow analysis based asset value of $717M for T2Dx instrument and test panels, with a 15% discount rate and 0% terminal growth rate, excluding $42M outstanding debt.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.1% and a 29.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.
T2 Biosystems has an analyst consensus of Moderate Buy, with a price target consensus of $12.50, implying a 136.7% upside from current levels. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $11 price target.
.
See today’s analyst top recommended stocks >>
Pacira Pharmaceuticals (PCRX)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Pacira Pharmaceuticals, with a price target of $60. The company’s shares closed yesterday at $52.16, close to its 52-week high of $52.67.
Livnat commented:
“We have always seen 2018 guidance as conservative ever since it was first issued in February, and we were already above the high end. New guidance implies 4Q18 YoY growth of 12-19% which, when considering the tougher 4Q17 comp, suggests steady continuation of the strong growth trend, which delivered nearly 20% YoY growth over the last six months. Crucially in our view, the Street is now seeing the operating leverage in Pacira’s operating model, particularly on the gross margin line. Given the high fixed-cost base and low variable cost of Exparel manufacturing, margin really jumps with higher sales.”
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 7.6% and a 61.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Jazz Pharmaceuticals, and Agile Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pacira Pharmaceuticals with a $54.31 average price target, implying a 4.1% upside from current levels. In a report issued on October 24, Jefferies also maintained a Buy rating on the stock with a $50 price target.
.
CymaBay Therapeutics (CBAY)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on CymaBay Therapeutics, with a price target of $23. The company’s shares closed yesterday at $11.21.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 15.5% and a 40.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Currently, the analyst consensus on CymaBay Therapeutics is a Strong Buy with an average price target of $22.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CBAY:
